Relmada Therapeutics (STU:4E2) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4E2 Relmada Therapeutics Inc STU:4E2
29 GF Score
Price €4.50
! 2 Warning Signs
View Full Analysis

What is Relmada Therapeutics FFO per Share?

FFO per Share only applies to REITs.

STU:4E2
29GF Score
Relmada Therapeutics Inc STU:4E2
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relmada Therapeutics Business Description

Other Exchanges RLMD:USA
Address 2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
29GF Score

Get the complete analysis for STU:4E2

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.50
Price